Question: Turbidimetric inhibition immunoassay may be used to test your blood if you have what condition?

Context paragraphs:
Digoxin: Digoxin, sold under the brand name Lanoxin among others, is a medication used to treat various heart conditions.  Most frequently it is used for atrial fibrillation, atrial flutter, and heart failure.  Digoxin is taken by mouth or by injection into a vein.

Galactorrhea hyperprolactinemia: Galactorrhea hyperprolactinemia is increased blood prolactin levels associated with galactorrhea (abnormal milk secretion).  It may be caused by such things as certain medications, pituitary disorders and thyroid disorders.  The condition can occur in males as well as females.  Relatively common etiologies include prolactinoma, medication effect, kidney failure, granulomatous diseases of the pituitary gland, and disorders which interfere with the hypothalamic inhibition of prolactin release.  Ectopic (non-pituitary) production of prolactin may also occur.  Galactorrhea hyperprolactinemia is listed as a “rare disease” by the Office of Rare Diseases of the National Institutes of Health.  This means that it affects less than 200,000 people in the United States population.

Immunoassay: An immunoassay is a biochemical test that measures the presence or concentration of a macromolecule or a small molecule in a solution through the use of an antibody (usually) or an antigen (sometimes).  The molecule detected by the immunoassay is often referred to as an "analyte" and is in many cases a protein, although it may be other kinds of molecules, of different size and types, as long as the proper antibodies that have the adequate properties for the assay are developed.  Analytes in biological liquids such as serum or urine are frequently measured using immunoassays for medical and research purposes.

Blood test: A blood test is a laboratory analysis performed on a blood sample that is usually extracted from a vein in the arm using a hypodermic needle, or via fingerprick.  Multiple tests for specific blood components, such as a glucose test or a cholesterol test, are often grouped together into one test panel called a blood panel or blood work.  Blood tests are often used in health care to determine physiological and biochemical states, such as disease, mineral content, pharmaceutical drug effectiveness, and organ function.  Typical clinical blood panels include a basic metabolic panel or a complete blood count.  Blood tests are also used in drug tests to detect drug abuse.  In some of the United States, a blood test is required before marriage.

CYP17A1 inhibitor: A CYP17A1 inhibitor is a type of drug which inhibits the enzyme CYP17A1.  It may inhibit both of the functions of the enzyme, 17α-hydroxylase and 17,20-lyase, or may be selective for inhibition of one of these two functions (generally 17,20-lyase).  These drugs prevent the conversion of pregnane steroids into androgens like testosterone and therefore are androgen biosynthesis inhibitors and functional antiandrogens. Examples of CYP17A1 inhibitors include the older drug ketoconazole and the newer drugs abiraterone acetate, orteronel, galeterone, and seviteronel.  The CYP17A1 inhibitors that have been marketed, like abiraterone acetate, are used mainly in the treatment of prostate cancer.  CYP17A1 inhibitors that are not selective for inhibition of 17,20-lyase must be combined with a glucocorticoid such as prednisone in order to avoid adrenal insufficiency caused by prevention of cortisol production.

(6S)-6-Fluoroshikimic acid: (6"S")-6-Fluoroshikimic acid is an antibacterial agent acting on the aromatic biosynthetic pathway.  It may be used against "Plasmodium falciparum", the causative agent of malaria.  The molecule is targeting the enzymes of the shikimate pathway.  This metabolic pathway is not present in mammals.  The mechanism of action of the molecule is not through the inhibition of chorismate synthase but by the inhibition of 4-aminobenzoic acid synthesis.

Epoxyeicosatrienoic acid: The epoxyeicosatrienoic acids or EETs are signaling molecules formed within various types of cells by the metabolism of arachidonic acid by a specific subset of Cytochrome P450 enzymes termed cytochrome P450 epoxygenases.  These nonclassic eicosanoids are generally short-lived, being rapidly converted from epoxides to less active or inactive dihydroxy-eicosatrienoic acids (diHETrEs) by a widely distributed cellular enzyme, Soluble epoxide hydrolase (sEH), also termed Epoxide hydrolase 2.  The EETs consequently function as transiently acting, short-range hormones; that is, they work locally to regulate the function of the cells that produce them (i.e. they are autocrine agents) or of nearby cells (i.e. they are paracrine agents).  The EETs have been most studied in animal models where they show the ability to lower blood pressure possibly by a) stimulating arterial vasorelaxation and b) inhibiting the kidney's retention of salts and water to decrease intravascular blood volume.  In these models, EETs prevent arterial occlusive diseases such as heart attacks and brain strokes not only by their anti-hypertension action but possibly also by their anti-inflammatory effects on blood vessels, their inhibition of platelet activation and thereby blood clotting, and/or their promotion of pro-fibrinolytic removal of blood clots.  With respect to their effects on the heart, the EETs are often termed cardio-protective.  Beyond these cardiovascular actions that may prevent various cardiovascular diseases, studies have implicated the EETs in the pathological growth of certain types of cancer and in the physiological and possibly pathological perception of neuropathic pain.  While studies to date imply that the EETs, EET-forming epoxygenases, and EET-inactivating sEH can be manipulated to control a wide range of human diseases, clinical studies have yet to prove this.  Determination of the role of the EETS in human diseases is made particularly difficult because of the large number of EET-forming epoxygenases, large number of epoxygenase substrates other than arachidonic acid, and the large number of activities, some of which may be pathological or injurious, that the EETs possess.

Latent inhibition: Latent inhibition is a technical term used in classical conditioning to refer to the observation that a familiar stimulus takes longer to acquire meaning (as a signal or conditioned stimulus) than a new stimulus.  The term "latent inhibition" dates back to Lubow and Moore.  The LI effect is "latent" in that it is not exhibited in the stimulus pre-exposure phase, but rather in the subsequent test phase.  "Inhibition", here, simply connotes that the effect is expressed in terms of relatively poor learning.  The LI effect is extremely robust, appearing in all mammalian species that have been tested and across many different learning paradigms, thereby suggesting some adaptive advantages, such as protecting the organism from associating irrelevant stimuli with other, more important, events.

Ocular ischemic syndrome: Ocular ischemic syndrome is the constellation of ocular signs and symptoms secondary to severe, chronic arterial hypoperfusion to the eye.  Amaurosis fugax is a form of acute vision loss caused by reduced blood flow to the eye; it may be a warning sign of an impending stroke, as both stroke and retinal artery occlusion can be caused by thromboembolism due to atherosclerosis elsewhere in the body (such as coronary artery disease and especially carotid atherosclerosis).  Consequently, those with transient blurring of vision are advised to urgently seek medical attention for a thorough evaluation of the carotid artery.  Anterior segment ischemic syndrome is a similar ischemic condition of anterior segment usually seen in post-surgical cases.  Retinal artery occlusion (such as central retinal artery occlusion or branch retinal artery occlusion) leads to rapid death of retinal cells, thereby resulting in severe loss of vision.

Turbidimetric inhibition immunoassay: Turbidimetric inhibition immuno assay (TINIA) is a type of immunoassay that uses turbidimetry as the measurement principle and is used for many commercial immunoassays, e.g. measurement of HbA1c%, Digoxin etc. in whole blood sample in several commercial assays employ this principle.

Supporting paragraphs: Turbidimetric inhibition immunoassay Digoxin
Answer: various heart conditions